These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1017 related items for PubMed ID: 29067469

  • 1. Long non‑coding RNA AK001796 contributes to cisplatin resistance of non‑small cell lung cancer.
    Liu B, Pan CF, Ma T, Wang J, Yao GL, Wei K, Chen YJ.
    Mol Med Rep; 2017 Oct; 16(4):4107-4112. PubMed ID: 29067469
    [Abstract] [Full Text] [Related]

  • 2. Downregulation of Meg3 enhances cisplatin resistance of lung cancer cells through activation of the WNT/β-catenin signaling pathway.
    Xia Y, He Z, Liu B, Wang P, Chen Y.
    Mol Med Rep; 2015 Sep; 12(3):4530-4537. PubMed ID: 26059239
    [Abstract] [Full Text] [Related]

  • 3. LncRNA NNT-AS1 is a major mediator of cisplatin chemoresistance in non-small cell lung cancer through MAPK/Slug pathway.
    Cai Y, Dong ZY, Wang JY.
    Eur Rev Med Pharmacol Sci; 2018 Aug; 22(15):4879-4887. PubMed ID: 30070323
    [Abstract] [Full Text] [Related]

  • 4. Downregulated long non-coding RNA TRPM2-AS inhibits cisplatin resistance of non-small cell lung cancer cells via activation of p53- p66shc pathway.
    Ma LY, Xie XW, Ma L, Pang JL, Xiong XM, Zheng HD, Shen XL, Wen ZG, Wang HY.
    Eur Rev Med Pharmacol Sci; 2017 Jun; 21(11):2626-2634. PubMed ID: 28678322
    [Abstract] [Full Text] [Related]

  • 5. Knockdown of lncRNA ANRIL inhibits the development of cisplatin resistance by upregulating miR‑98 in lung cancer cells.
    Wang X, Zhang G, Cheng Z, Dai L, Jia L, Jing X, Wang H, Zhang R, Liu M, Jiang T, Yang Y, Yang M.
    Oncol Rep; 2020 Sep; 44(3):1025-1036. PubMed ID: 32705261
    [Abstract] [Full Text] [Related]

  • 6. Long noncoding LUCAT1 promotes cisplatin resistance of non-small cell lung cancer by promoting IGF-2.
    Wang W, Dong ML, Zhang W, Liu T.
    Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5229-5234. PubMed ID: 31298373
    [Abstract] [Full Text] [Related]

  • 7. Long non‑coding RNA LUCAT1 contributes to cisplatin resistance by regulating the miR‑514a‑3p/ULK1 axis in human non‑small cell lung cancer.
    Shen Q, Xu Z, Xu S.
    Int J Oncol; 2020 Oct; 57(4):967-979. PubMed ID: 32945379
    [Abstract] [Full Text] [Related]

  • 8. Upregulation of Long Noncoding RNA (lncRNA) X-Inactive Specific Transcript (XIST) is Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer (NSCLC) by Downregulating MicroRNA-144-3p.
    Tian LJ, Wu YP, Wang D, Zhou ZH, Xue SB, Zhang DY, Wei YG, Liu W.
    Med Sci Monit; 2019 Oct 29; 25():8095-8104. PubMed ID: 31659146
    [Abstract] [Full Text] [Related]

  • 9. The Long Noncoding RNA MEG3 Contributes to Cisplatin Resistance of Human Lung Adenocarcinoma.
    Liu J, Wan L, Lu K, Sun M, Pan X, Zhang P, Lu B, Liu G, Wang Z.
    PLoS One; 2015 Oct 29; 10(5):e0114586. PubMed ID: 25992654
    [Abstract] [Full Text] [Related]

  • 10. Effect of lncRNA-BLACAT1 on drug resistance of non-small cell lung cancer cells in DDP chemotherapy by regulating cyclin D1 expression.
    Ju ZS, Sun B, Bao D, Zhang XF.
    Eur Rev Med Pharmacol Sci; 2020 Sep 29; 24(18):9465-9472. PubMed ID: 33015788
    [Abstract] [Full Text] [Related]

  • 11. LncRNA SNHG14 regulates the DDP-resistance of non-small cell lung cancer cell through miR-133a/HOXB13 pathway.
    Xu L, Xu Y, Yang M, Li J, Xu F, Chen BL.
    BMC Pulm Med; 2020 Oct 15; 20(1):266. PubMed ID: 33059643
    [Abstract] [Full Text] [Related]

  • 12. Long noncoding RNA OR3A4 promotes cisplatin resistance of non-small cell lung cancer by upregulating CDK1.
    Shang J, Xu YD, Zhang YY, Li M.
    Eur Rev Med Pharmacol Sci; 2019 May 15; 23(10):4220-4225. PubMed ID: 31173293
    [Abstract] [Full Text] [Related]

  • 13. siRNA silencing EZH2 reverses cisplatin-resistance of human non-small cell lung and gastric cancer cells.
    Zhou W, Wang J, Man WY, Zhang QW, Xu WG.
    Asian Pac J Cancer Prev; 2015 May 15; 16(6):2425-30. PubMed ID: 25824776
    [Abstract] [Full Text] [Related]

  • 14. Increased ABCC2 expression predicts cisplatin resistance in non-small cell lung cancer.
    Chen Y, Zhou H, Yang S, Su D.
    Cell Biochem Funct; 2021 Mar 15; 39(2):277-286. PubMed ID: 32815556
    [Abstract] [Full Text] [Related]

  • 15. Silence of  lncRNA UCA1 rescues drug resistance of cisplatin to non-small-cell lung cancer cells.
    Liu X, Huang Z, Qian W, Zhang Q, Sun J.
    J Cell Biochem; 2019 Jun 15; 120(6):9243-9249. PubMed ID: 30652341
    [Abstract] [Full Text] [Related]

  • 16. GAS5 knockdown reduces the chemo-sensitivity of non-small cell lung cancer (NSCLC) cell to cisplatin (DDP) through regulating miR-21/PTEN axis.
    Cao L, Chen J, Ou B, Liu C, Zou Y, Chen Q.
    Biomed Pharmacother; 2017 Sep 15; 93():570-579. PubMed ID: 28686971
    [Abstract] [Full Text] [Related]

  • 17. NORAD accelerates chemo-resistance of non-small-cell lung cancer via targeting at miR-129-1-3p/SOX4 axis.
    Huang Q, Xing S, Peng A, Yu Z.
    Biosci Rep; 2020 Jan 31; 40(1):. PubMed ID: 31894841
    [Abstract] [Full Text] [Related]

  • 18. Inhibition of microRNA-196a might reverse cisplatin resistance of A549/DDP non-small-cell lung cancer cell line.
    Li JH, Luo N, Zhong MZ, Xiao ZQ, Wang JX, Yao XY, Peng Y, Cao J.
    Tumour Biol; 2016 Feb 31; 37(2):2387-94. PubMed ID: 26376998
    [Abstract] [Full Text] [Related]

  • 19. Circular RNA hsa_circ_0096157 contributes to cisplatin resistance by proliferation, cell cycle progression, and suppressing apoptosis of non-small-cell lung carcinoma cells.
    Lu H, Xie X, Wang K, Chen Q, Cai S, Liu D, Luo J, Kong J.
    Mol Cell Biochem; 2020 Dec 31; 475(1-2):63-77. PubMed ID: 32767026
    [Abstract] [Full Text] [Related]

  • 20. SNHG7 mediates cisplatin-resistance in non-small cell lung cancer by activating PI3K/AKT pathway.
    Chen K, Abuduwufuer A, Zhang H, Luo L, Suotesiyali M, Zou Y.
    Eur Rev Med Pharmacol Sci; 2019 Aug 31; 23(16):6935-6943. PubMed ID: 31486493
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 51.